arrow
S

Shujun Luo

harbin fulin
H指数:47
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors

首次人体、I期研究:CBP-1008(一种首创的双特异性配体药物偶联物[Bi-XDC])在晚期实体瘤患者中的应用

2024-09-010
PRE
YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study

YL201,一种新型的B7H3靶向抗体药物偶联物(ADC),在晚期实体瘤患者(pts)中的研究:来自一项首次人体I期研究的结果

2024-09-013
PRE
Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)
2022-02-150
PRE